Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Links shared publicly online about this topic.

466
total visits

Infinity commences IPI-926 Phase 2 clinical trial in rare, life-threatening bone cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of IPI-926 compared to placebo in patients with metastatic or locally advanced, inoperable chondrosarcoma. The trial is expected to enroll over 100 patients worldwide.

View full resource at news-medical.net

Tags: Cancer, Bone Cancer, Bone, Pharma, Phase 2 Clinical Trial, Clinical Trial, Oncology, News